Free tool
Stocks above their 200-day average
We cover 45 companies trading above their own 200-day average. The median market value in the group is $16.99B. Across the group, the median move over the past trading day is +0.52%. 100% of the 45 with a 200-day average trade above it. Price change over the past year runs from −11.1% to +140.6% across the middle 80 percent of the group, with a median of +29.1%.
Other lists in this group
Table
45 of 10,735 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | $658.24B | Mega cap | +55.40% | Oct 13, 2026 |
| JNJ.DE | Johnson & Johnson | $651.71B | Mega cap | +58.93% | Oct 13, 2026 |
| NOT.DE | Novartis AG | $300.14B | Mega cap | +28.89% | Oct 27, 2026 |
| NVS | Novartis AG | $299.44B | Mega cap | +27.93% | Oct 27, 2026 |
| TMO | Thermo Fisher Scientific Inc. | $234.31B | Mega cap | +30.17% | Oct 21, 2026 |
| TN8.DE | Thermo Fisher Scientific Inc. | $234.00B | Mega cap | +29.67% | Oct 21, 2026 |
| ABL.DE | Abbott Laboratories | $200.44B | Mega cap | −10.02% | Oct 14, 2026 |
| ABT | Abbott Laboratories | $198.74B | Large cap | −11.83% | Oct 14, 2026 |
| DAP.DE | Danaher Corporation | $151.59B | Large cap | +6.90% | Oct 20, 2026 |
| DHR | Danaher Corporation | $151.40B | Large cap | +5.61% | Oct 20, 2026 |
| MDT | Medtronic plc | $117.78B | Large cap | +2.29% | Sep 1, 2026 |
| 2M6.DE | Medtronic plc | $117.57B | Large cap | +2.65% | Sep 1, 2026 |
| ELV | Elevance Health, Inc. | $87.30B | Large cap | +32.12% | Oct 21, 2026 |
| ARGX | argenx SE | $65.51B | Large cap | +47.90% | Oct 22, 2026 |
| CNC | Centene Corporation | $32.34B | Large cap | +127.01% | Oct 27, 2026 |
| DGX | Quest Diagnostics Incorporated | $26.99B | Large cap | +38.12% | Oct 20, 2026 |
| INCY | Incyte Corporation | $25.97B | Large cap | +51.01% | Oct 27, 2026 |
| WST | West Pharmaceutical Services, Inc. | $24.63B | Large cap | +42.61% | Oct 22, 2026 |
| THC | Tenet Healthcare Corporation | $21.89B | Large cap | +50.70% | Oct 27, 2026 |
| DIM.PA | Sartorius Stedim Biotech S.A. | $21.78B | Large cap | +11.64% | Oct 22, 2026 |
| 56S1.DE | Sartorius Stedim Biotech S.A. | $21.77B | Large cap | +11.32% | Oct 22, 2026 |
| MEDP | Medpace Holdings, Inc. | $17.28B | Large cap | +30.74% | Oct 19, 2026 |
| SOBI.ST | Swedish Orphan Biovitrum AB (publ) | $16.99B | Large cap | +61.26% | Oct 27, 2026 |
| SRT.DE | Sartorius Aktiengesellschaft | $15.54B | Large cap | +21.79% | Oct 22, 2026 |
| EXEL | Exelixis, Inc. | $14.05B | Large cap | +45.68% | Oct 27, 2026 |
| RVTY | Revvity, Inc. | $13.93B | Large cap | +42.93% | Oct 26, 2026 |
| ICLR | ICON Public Limited Company | $13.03B | Large cap | −2.91% | Oct 21, 2026 |
| BMRN | BioMarin Pharmaceutical Inc. | $12.70B | Large cap | +11.85% | Oct 26, 2026 |
| MOH | Molina Healthcare, Inc. | $10.57B | Large cap | +13.35% | Oct 21, 2026 |
| CHE | Chemed Corporation | $7.11B | Mid cap | +20.79% | Oct 27, 2026 |
| GETI-B.ST | Getinge AB (publ) | $7.01B | Mid cap | +20.89% | Oct 21, 2026 |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.05B | Mid cap | +133.47% | Oct 27, 2026 |
| SECT-B.ST | Sectra AB (publ) | $5.63B | Mid cap | −17.02% | Sep 4, 2026 |
| RCUS | Arcus Biosciences, Inc. | $3.92B | Mid cap | +191.29% | Oct 27, 2026 |
| NRIX | Nurix Therapeutics, Inc. | $2.77B | Mid cap | +179.69% | Oct 8, 2026 |
| WGS | GeneDx Holdings Corp. | $2.69B | Mid cap | −30.11% | Oct 27, 2026 |
| NEOG | Neogen Corporation | $2.54B | Mid cap | +103.83% | Oct 8, 2026 |
| ATRC | AtriCure, Inc. | $2.45B | Mid cap | +29.14% | Oct 27, 2026 |
| 3549.T | Kusuri No Aoki Holdings Co., Ltd. | $2.44B | Mid cap | +5.23% | Oct 1, 2026 |
| NEO | NeoGenomics, Inc. | $2.26B | Mid cap | +145.34% | Oct 27, 2026 |
| NBTX | Nanobiotix S.A. | $2.26B | Mid cap | +394.99% | Sep 29, 2026 |
| ALIF-B.ST | AddLife AB (publ) | $2.08B | Mid cap | −7.20% | Oct 21, 2026 |
| NANO.PA | Nanobiotix S.A. | $2.05B | Mid cap | +358.21% | Sep 29, 2026 |
| INTEG-B.ST | Integrum AB (publ) | $24.72M | Micro cap | −79.55% | Sep 3, 2026 |
| INM | InMed Pharmaceuticals Inc. | $7.64M | Micro cap | −36.44% | Sep 23, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.